Sanofi (NASDAQ:SNY) Shares Sold by Banco de Sabadell S.A

Banco de Sabadell S.A decreased its position in Sanofi (NASDAQ:SNY) by 3.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,662 shares of the company’s stock after selling 763 shares during the period. Banco de Sabadell S.A’s holdings in Sanofi were worth $898,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Abel Hall LLC raised its stake in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after purchasing an additional 194 shares during the last quarter. Keudell Morrison Wealth Management raised its position in Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after buying an additional 217 shares during the last quarter. Bailard Inc. lifted its stake in Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after acquiring an additional 220 shares during the period. Old Port Advisors boosted its holdings in shares of Sanofi by 0.6% in the 4th quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after acquiring an additional 232 shares during the last quarter. Finally, ORG Partners LLC increased its stake in shares of Sanofi by 17.7% in the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock worth $81,000 after acquiring an additional 253 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Price Performance

NASDAQ:SNY opened at $56.90 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The stock’s 50-day moving average price is $54.55 and its 200-day moving average price is $52.89. The stock has a market capitalization of $144.40 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SNY shares. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday. They set a “neutral” rating and a $65.00 target price for the company. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.